Spinocerebellar ataxia type 7 (SCA7) is an autosomal dominant neurodegenerative disorder characterized by cerebellar and retinal degeneration, and is caused by a CAG-polyglutamine repeat expansion in the ATAXIN-7 gene. Patients with SCA7 develop progressive cone-rod dystrophy, typically resulting in blindness. Antisense oligonucleotides (ASOs) are single-stranded chemically modified nucleic acids designed to mediate the destruction, prevent the translation, or modify the processing of targeted RNAs. Here, we evaluated ASOs as treatments for SCA7 retinal degeneration in representative mouse models of the disease after injection into the vitreous humor of the eye. Using Ataxin-7 aggregation, visual function, retinal histopathology, gene expression, and epigenetic dysregulation as outcome measures, we found that ASO-mediated Ataxin-7 knockdown yielded improvements in treated SCA7 mice. In SCA7 mice with retinal disease, intravitreal injection of Ataxin-7 ASOs also improved visual function despite initiating treatment after symptom onset. Using color fundus photography and autofluorescence imaging, we also determined the nature of retinal degeneration in human SCA7 patients. We observed variable disease severity and cataloged rapidly progressive retinal degeneration. Given the accessibility of neural retina, availability of objective, quantitative readouts for monitoring therapeutic response, and the rapid disease progression in SCA7, ASOs targeting ATAXIN-7 might represent a viable treatment for SCA7 retinal degeneration.
INTRODUCTION
Spinocerebellar ataxia type 7 (SCA7) is an autosomal dominant neuro degenerative disorder characterized by cerebellar ataxia, dysarthria, ophthalmoplegia, hyperreflexia, spasticity, and retinal degeneration (1) . Although the disease is rare, affecting ~1 of 500,000 individuals, SCA7 exhibits a wide geographic distribution, occurring in all major racial groups and various ethnic populations (2, 3) . SCA7 is caused by a CAGpolyglutamine (polyQ) repeat expansion at the 5′ end of the coding region of the ATAXIN-7 gene (4, 5) . Although normal individuals have alleles ranging in size from 7 to 35 CAGs, disease causing expanded SCA7 CAG repeats are among the most unstable of all coding repeat expansions, with patients having 37 to >300 repeats (5) . Anticipation is notable in SCA7 pedigrees, with the longest repeat mutations producing infantile onset (6) (7) (8) . Larger repeat expansions occur in male germ lines, and anticipation is sometimes so pro nounced that paternal transmission of SCA7 is associated with in creased spontaneous miscarriage rates in affected kindreds (6, 9) . There are nine recognized CAGpolyQ repeat diseases, including spinobulbar muscular atrophy, Huntington's disease (HD), dentatorubral pallidoluysian atrophy, and six forms of spinocerebellar ataxia (SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17). Numerous lines of investiga tion have shown that the initiating event in disease pathogenesis is misfolding of the polyQ expansion tract to an altered conformation that is resistant to protein degradation (10, 11) , indicating that SCA7 shares a common pathogenic basis with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and tauopathies.
The ATAXIN7 protein was identified as a novel polypeptide of unknown function with ubiquitous expression. Experiments in Saccharomyces cerevisiae revealed that mammalian ATAXIN7 has a yeast ortholog Sgf73, which is a core component of the Spt7Ada1 Gcn5 acetyltransferase transcription (SAGA) coactivator complex (12) , whereas independent studies concomitantly identified ATAXIN7 as a core component of the mammalian Spt3Taf9AdaGcn5 acetyl transferase (STAGA) transcription coactivator complex and closely re lated TATA binding proteinfree TAFcontaining complex (13, 14) . The STAGA complex has both histone acetyltransferase and histone deubiquitinase activity, and although the exact function of ATAXIN7 is unknown, it has been shown that polyQ-ATAXIN7 can integrate into the STAGA complex and alter the histone acetyltransferase ac tivity of STAGA in retinal photoreceptor cells (14, 15) .
SCA7 can be distinguished clinically from the other SCAs by the presence of retinal degeneration. Although fundoscopic examination typically shows degeneration of the macula, electrophysiological eval uation of SCA7 patients by electroretinogram (ERG) analysis reveals marked cone photoreceptor cell dysfunction throughout the retina before any rod photoreceptor abnormality (16) . Because cone photo receptor function precedes rod photoreceptor function, and this cone photoreceptor dysfunction is not restricted to one particular region of the retina, SCA7 fulfills the diagnostic criteria for conerod dystrophy (16) . Because cone photoreceptors mediate color vision, SCA7 pa tients can present with asymptomatic dyschromatopsia, which pre vents them from distinguishing the color yellow from the color blue (17) . The conerich macula is located in the central region of the retina; hence, SCA7 patients first complain of problems with central vision and often develop central scotomas (18) . However, as SCA7 retinal disease progresses, rod photoreceptor cells also become af fected, resulting in complete blindness.
Expression of polyQ disease proteins in cells and model organisms can disrupt a wide range of cellular processes, including proteasome dependent protein degradation, axonal transport, mitochondrial function, macroautophagy, neuroinflammation, glutamate transport, and synaptic transmission (19) . For these reasons, the development of a meaningful therapy to treat SCA7 and related polyQ disorders has been especially challenging. However, with the realization that these diseases all stem from the production of a mutant gene product, investigators hypothesized that targeting the mutant protein for de struction or preventing its production would interrupt the patho genic cascade at its very first step. One approach for gene silencing is use of an antisense oligonucleotide (ASO) to target the RNA. This technique uses synthetic single strands of 15 to 25 nucleotides of perfect (or nearperfect) sequence complementary to bind to a tar get RNA and thereby produce a DNARNA heteroduplex that is a substrate for degradation by ribonuclease (RNase) H or will inter fere with RNA processing or translation (20) .
Although ASOs were initially developed nearly three decades ago, advances in oligonucleotide synthesis and chemical modifica tion technologies have enabled this technology to move forward as a viable therapeutic strategy in humans, with the drug Spinraza ap proved for use in patients with autosomal recessive spinal muscular atrophy (21) . As a treatment for neurodegenerative diseases involv ing production of a toxic gene product, ASO therapy is emerging as an extremely promising approach, with clinical trials currently un derway in adult patients with familial ALS due to dominant SOD1 mutations (NCT02623699) and a phase 1/2a clinical trial in early stage HD patients (NCT02519036). Furthermore, a recent study of SCA2 demonstrated that central nervous system (CNS) delivery of Ataxin-2 ASO can effectively treat the dysfunction and degenera tion of Purkinje neurons of the cerebellum in mouse models of this disorder (22) .
Because considerable experience with ASO knockdown in related neurodegenerative diseases augurs well for the utility and likely fea sibility of this regimen in human patients, we initiated a drug dis covery campaign focused on the creation of an ASO therapy for SCA7. This work pursued a twopronged approach to reducing Ataxin-7 RNA expression, comparing an ASO targeting the Ataxin-7 mRNA with an ASO targeting the extended CAG repeat tract. We chose to examine these different ASOs as a treatment for SCA7 retinal de generation because the conerod dystrophy phenotype of SCA7 of fers the unique opportunity to evaluate this therapeutic strategy in a highly accessible neural tissue-the eye, with disease outcome measures that are highly objective and quantitative. Hence, ASO therapy development for SCA7 retinal degeneration represents an im portant proofofconcept opportunity for discretely and definitively assessing the true potential of the dosage reduction paradigm as a treatment for neurodegeneration.
RESULTS
Intravitreal injection yields safe, effective suppression of retinal Ataxin-7 RNA expression To obtain Ataxin-7-specific ASOs with superior potency and minimal likelihood for toxicity, we synthesized ~150 Ataxin-7 ASOs directed against mouse Ataxin-7. These ASOs were synthesized as high affinity oligonucleotides, composed of constrained ethyl nucleoside analogs that lock the sugar backbone into a bridged nucleic acid structure to promote binding affinity and thus increase potency by a factor of 5 to 10 in comparison to the previous generation 2′O methoxyethyl ASO design (23) . Synthesized ASOs were screened for Ataxin-7 knockdown in a mouse endothelial cell line, yielding ~25 hits that exhibited >75% knockdown at modest concentrations ( fig. S1 ). Secondary screening of the top 12 ASOs was completed in vivo to identify the best tolerated Ataxin-7 ASO with the least toxicity, and on the basis of this secondary screening, ASO #144 was selected as the most promising lead for in vivo studies.
To achieve delivery of oligonucleotides to retinal neurons and to photoreceptors in particular, we performed injections of oligonu cleotides into the vitreous humor, as previous work has shown that intravitreal injection (IVI) permits diffusion throughout the eye, including to retinal photoreceptors (24) . To validate the IVI delivery technique, we pursued a series of proofofprinciple experiments with a Rhodopsin ASO (25) . Rhodopsin is expressed in retinal photo receptors; hence, IVI of the Rhodopsin ASO will only result in knock down of Rhodopsin gene expression in the eye, if the oligonucleotide distributes to retinal photoreceptor neurons. We performed 1l IVI of Rhodopsin ASO at a concentration of 50 g/l in the right eye of control mice, along with 1l IVI of diluent [phosphatebuffered saline (PBS)] into the contralateral left eye. Reverse transcription polymerase chain reaction (RTPCR) quantification of Rhodopsin expression in RNAs isolated from harvested retinas of treated mice showed Rhodopsin knockdown ranging from 65 to 95%, for an overall mean knockdown of ~70%, which was significant (P < 0.01; fig. S2 , A and B), consistent with previous work using ASOs targeting rho dopsin (25) . Robust knockdown of rhodopsin upon IVI of an anti rhodopsin ASO thus confirmed our ability to achieve delivery to retinal photoreceptors using this method.
To determine the optimal dosage for Ataxin-7 knockdown by ASO #144, we performed a series of IVI experiments in C57BL/6J mice, comparing dosages ranging from 12.5 to 50 g, and observed >70% knockdown of Ataxin-7 RNA expression in the retinas of mice treated with the 50g dose (Fig. 1A) . We selected 50 g as the ideal dosage, because we observed occasional toxicity at doses of 75 g. To evaluate the duration of oligonucleotide knockdown using the IVI delivery technique, we injected 1 l of Ataxin-7 ASO #144 intra vitreal at a concentration of 50 g/l in the right eye of 18 C57BL/6J mice and 1l IVI of vehicle (PBS) into the contralateral left eye of the same 18 C57BL/6J mice and then euthanized mice at different time points after IVI. We noted >50% knockdown of Ataxin-7 RNA expression out to 4 weeks after injection and documented >40% knockdown at the final 6week postinjection time point (Fig. 1B) . We also examined distribution of the ASO by immunostaining ret inal sections from mice subjected to IVI with an antibody directed against the oligonucleotide backbone and detected Ataxin-7 ASO throughout the neural retina at 1 and 6 weeks after injection (Fig. 1,  C and D) . These findings suggest that ASO #144 is effective in knocking down Ataxin-7 in the retina.
Ataxin-7 ASO achieves marked reductions in Ataxin-7 expression and protein aggregation in the eyes of treated SCA7 knock-in mice SCA7 is unique among the SCAs, because SCA7 patients suffer from an unusual form of retinal degeneration, known as conerod dystrophy. We and others have accurately recapitulated SCA7 conerod dystrophy retinal degeneration in mice (26, 27) . The availability of such mouse models permits testing of potential therapies. To ascertain whether ASOmediated knockdown of Ataxin-7 might be an effective treatment for SCA7 retinal degeneration, we performed a preclinical study with Ataxin-7 ASO #144. For the study, we selected an aggressive juvenile onset-like mouse model of SCA7, known as the SCA7 266Q "knock in" model, because a 266CAG repeat contained on a small DNA fragment from the human ATAXIN-7 gene was inserted into the endogenous mouse Ataxin-7 locus (27) . The first signs of ERG visual impairment in SCA7 266Q knockin mice occur at ~5 weeks of age (27) . To determine whether intravitreal delivery of Ataxin-7 ASO is capable of ameliorating the rapidly progressive retinal degeneration in SCA7 266Q knockin mice, we performed onetime 1l IVI of Ataxin-7 ASO at a concentration of 50 g/l into the right eye of SCA7 266Q knockin mice at 4 weeks of age, along with a onetime 1l IVI of PBS into the left eye. Detectable visual impairment typi cally occurs by 6 weeks of age in SCA7 266Q knockin mice, which succumb to disease by 10 to 11 weeks of age. For these reasons, we designed a preclinical prevention trial in which we followed cohorts of mice for 6 weeks for a variety of outcome measures ( fig. S3) . We began by measuring Ataxin-7 RNA expression in the retinas of treated SCA7 266Q knock in mice at 6 weeks after IVI and confirmed that Ataxin-7 ASOtreated eyes displayed >60% reduction in Ataxin-7 RNA expression in compar ison to vehicletreated eyes ( Fig. 2A) . One important read out for therapeutic response is the extent of aggregation of polyQ-Ataxin7, because aggregate burden often cor relates with the quantity of toxic soluble protein or oligo mer species. To assess polyQAtaxin7 aggregation in neural retina, we immunostained ret inas from treated SCA7 266Q knockin mice at 6 weeks af ter IVI and observed a marked reduction in aggregates in ret inal neurons, especially photo receptors (Fig. 2B) . To quantify the extent of aggregate reduc tion in treated SCA7 266Q knock in mice, we performed filter trap assays on protein lysates prepared from indi vidual retinas, comparing Ataxin-7 ASOtreated retin as with vehicle treated retin as, and noted a significant decrease (P < 0.001) in the amount of aggregated polyQAtaxin7 protein in ASOtreated retinas (Fig. 2, C and D) . To determine the extent to which the Ataxin-7 ASO targets the normal repeatlength Ataxin-7 allele, we performed immunoblot analysis of Ataxin-7 ASOtreated retinas of SCA7 266Q knockin mice and observed marked reductions of both insoluble, polyQexpanded, aggregated Ataxin7 and normal Qlength, soluble Ataxin7 in comparison to diluenttreated retinas ( fig. S4 , A to C).
Ataxin-7 ASO ameliorates vision loss in SCA7 knock-in mice
Although reduction in polyQ-Ataxin7 protein aggregation upon ASO IVI is encouraging, the status of visual function in response to ASO treatment is a crucial outcome measure for judging potential therapeutic efficacy. To assess visual function, we performed ERG analysis of ASOtreated SCA7 266Q knockin mice at 4 and 6 weeks after IVI, comparing IVI of Ataxin-7 ASO with IVI of a scrambled control ASO or of the vehicle PBS. We began by evaluating cone specific photopic responses and documented enhanced cone photo receptor function in the eyes of SCA7 266Q knockin mice treated with Ataxin-7 ASO at both 4 and 6 weeks after IVI (Fig. 3) . On the basis of comparison of cone photoreceptor maximal bwave ampli tudes, Ataxin-7 ASOtreated eyes of SCA7 266Q mice displayed increased visual function at 4 weeks after IVI compared to vehicle treated eyes or control ASO-treated eyes (Fig. 3 , A and B) and re tained good visual function at 6 weeks after IVI (Fig. 3 , C and D). In the case of rod photoreceptor function, ERG analysis of scotopic responses revealed an even more favorable outcome, as Ataxin-7
ASOtreated eyes of SCA7 266Q mice retained normal visual func tion at 4 weeks after IVI (Fig. 4 , A and B) and maintained excellent visual function at 6 weeks after IVI (Fig. 4 , C and D). At both time points, the maximal bwave amplitudes of rod photoreceptors in SCA7 266Q knockin mice were found to be markedly increased with Ataxin-7 ASO treatment in comparison to control ASO treat ment or vehicle treatment (Fig. 4) , although even with ASO treat ment there is a slight delay in achieving maximal bwave amplitude in comparison to nontransgenic littermate controls, which reflects a slowed response in SCA7 retinal disease. In addition to evaluating the response to ASO IVI in the eyes of treated SCA7 266Q mice, we performed a series of IVI experiments comparing Ataxin-7 ASO treatment to vehicle treatment in normal control C57BL/6J mice to determine whether knockdown of normal Ataxin7 delete riously affects visual function. We observed no differences in cone or rod photoreceptor responses between ASOtreated eyes and vehicle treated eyes on ERG analysis in treated wildtype control mice ( fig. S5, A 
and B).
Ataxin-7 ASO rescues retinal histopathology, photoreceptor gene expression defects, and altered chromatin remodeling in the eyes of treated SCA7 knock-in mice Another important readout of retinal degeneration is thinning of the different layers that comprise the retina. To determine whether Ataxin7 knockdown affects this pathological process, we per formed hematoxylin and eosin staining of retinal sections from treated SCA7 266Q knockin mice. SCA7induced thinning was re duced in the outer segments (OSs) and inner segments (ISs) of retinal photoreceptors, the outer nuclear layer (ONL) that comprises the nuclei of photoreceptors, and the inner plexiform layer (IPL) that comprises the axonal projections of relay neurons whose nuclei are located in the inner nuclear layer (INL) in Ataxin-7 ASOtreated eyes in comparison to vehicle treatment (Fig. 5, A and B) . In addition to this histopathology, we and others have shown that SCA7 retinal degeneration is characterized by decreased expression of certain photoreceptorexpressed genes (26, 27) . To assess whether Ataxin7 knockdown ameliorates SCA7 retinal disease-associated gene ex pression alterations, we performed RTPCR analysis of retinal RNAs of three genes previously shown to be downregulated in SCA7 266Q knockin mice: Rhodopsin, M-opsin, and S-opsin. We documented an amelioration of expression reduction for all three genes in Ataxin-7 ASOtreated eyes compared to vehicletreated SCA7 266Q knockin mice (Fig. 5C ) but observed no effect of Ataxin-7 ASO treatment on genes whose expression is not altered in diseased SCA7 retinas ( fig. S6, A and B) . Because Ataxin7 protein is a core component of a transcription coactivator complex known as STAGA (13, 14) , and mutant polyQ-Ataxin7 interferes with STAGA dependent chromatin remodeling to impair transcription of STAGA regulated genes, we performed chromatin immunoprecipitation (ChIP) of histone modifications subject to STAGA regulation on retinal DNAs isolated from Ataxin-7 ASOtreated and vehicletreated eyes from SCA7 266Q knockin mice. We measured histone modi fication as a function of wildtype control by qPCR analysis of ChIP'd DNAs and documented rescue of altered histone H2B deu biquitination and histone H3 acetylation in Ataxin-7 ASOtreated eyes from SCA7 266Q knockin mice (Fig. 5, D and E) . Quantification of histone H3 acetylation at the promoter of the interphotoreceptor retinoid binding protein (IRBP) gene, whose expression is not altered in SCA7 retinal degeneration, revealed no evidence for a general effect of Ataxin-7 ASO treatment on histone H3 acetylation at retinal expressed genes ( fig. S6C ). These findings indicate that Ataxin-7 ASOmediated knockdown ameliorates SCA7 retinal degeneration at the cellular, molecular, and biochemical level.
CAG repeat-targeting ASO transiently ameliorates SCA7 retinal disease phenotypes
Because SCA7 is an autosomal dominant disorder in which the CAG repeat length of the normal allele is usually only 10 or 11 CAGs, and the CAG repeat length of the diseasecausing expanded allele ranges from 37 to 300+ CAGs in affected patients, with many SCA7 pa tients carrying disease alleles with >50 CAG repeats, another possible strategy for ASO therapy would be to selectively target the expanded CAG repeat tract of the mutant Ataxin-7 gene (28). We thus synthe sized a small set of CAG repeat-targeting oligonucleotides, and on the basis of in vivo safety testing, we narrowed down these leads to two CAG repeat-targeting ASOs, which were then tested in SCA7 patient fibroblasts. The results of these studies indicated superior knockdown of polyQ-ATAXIN7 protein expression by CAG ASO #2 ( fig. S7, A and B) ; hence, we selected this CAG repeat-targeting ASO for therapeutic evaluation in a preclinical prevention trial, identical in design to the Ataxin-7 ASO study just described. IVI of this CAG repeat-targeting ASO into the right eye of SCA7 266Q knockin mice did not reduce endogenous normal Ataxin7 protein ( fig. S8A ), as expected, because the mouse Ataxin-7 gene contains only five CAG repeats. IVI of CAG repeat-targeting ASO into the right eye of SCA7 266Q knockin mice did achieve a reduction in Ataxin7 protein aggregation based on immunostaining of retinal sections and filter trap analysis (Fig. 6, A and B) . However, inspec tion of the filter trap assay results indicated that reduction of pro tein aggregation at 6 weeks after IVI was often modest ( fig. S8B ), particularly when compared to treatment with the Ataxin-7 ASO. Thus, although CAGASO treatment did initially yield improved visual function at 4 weeks after IVI in SCA7 266Q knockin mice in com parison to vehicle treatment (Fig. 6C) , by 6 weeks after IVI, visual function was not different between CAGASO-treated eyes and vehicletreated eyes (Fig. 6D) . Results for retinal morphology analysis paralleled the findings observed for visual function, as CAGASOtreated eyes displayed thicker OSs and ISs, ONL, and IPL at 4 weeks after IVI ( fig. S8C ). Thus, CAGASO therapy could preserve the morphologies of SCA7 266Q knockin retinas and did improve vi sual function in treated eyes at 4 weeks after IVI, but less so than the Ataxin-7 ASO approach that promoted RNase H1-mediated de struction of the Ataxin-7 RNA. Moreover, by 6 weeks after IVI, there was no benefit in the eyes of SCA7 266Q knockin mice un dergoing treatment with the CAG repeat-targeting ASO.
Human SCA7 patients display variable severity of retinal degeneration and rapid retinal disease progression Although ASOs achieved therapeutic efficacy in preclinical experi mentation in mice where treatment is initiated before onset of SCA7 retinal degeneration, a crucial question is whether therapeutic ben efit can be derived after SCA7 patients develop obvious disease. To better understand the clinical features of SCA7 retinal degeneration and the rapidity of its progression, we performed a series of oph thalmologic evaluations on two unrelated SCA7 patients and mon itored disease progression in one patient. We began by performing color fundus photography and autofluorescence imaging on the retina of SCA7 patient #1, a 55yearold woman with a 40CAG re peat allele, and observed minimal foveal autofluorescence changes (Fig. 7A, top) . In contrast, when we evaluated SCA7 patient #2, a 36yearold woman with a 51CAG repeat allele, we observed mod erate foveal hypoautofluorescence at the initial evaluation (Fig. 7A,  middle) , which progressed to markedly increased hypoautofluores cence at her 3year followup examination (Fig. 7A, bottom) . We also obtained crosssectional images of the retina by optical coherence tomography (OCT), which yielded a nearly normalappearing retina in mildly affected patient #1 (Fig. 7B, top) but re vealed obvious retinal pathology in patient #2 at initial presentation (Fig. 7B, middle) that wors ened to much more extensive retinal pathology at her 3year followup examination (Fig. 7B, bottom) . Last, we performed a functional evaluation with microperimetry on these two SCA7 patients. We noted a mild deficit in retinal sensitivity in pa tient #1 (Fig. 7C, top) but a severe deficit in retinal sensitivity in patient #2 (Fig. 7C, bottom) . These clinical studies demonstrated the variability in retinal disease in different SCA7 patients and doc umented the fast progression of SCA7 retinal degeneration.
Ataxin-7 ASO therapy after disease onset can ameliorate retinal degeneration in SCA7 266Q knock-in mice
Given the likelihood of significant preexisting retinal disease at the time of presentation in SCA7 patients, we sought to perform a preclinical study initiating the treatment after the appearance of marked visual impairment. Because the SCA7 266Q knockin mice display a very severe pheno type with death as early as 10 weeks of age, the window of time for tracking therapeutic response after disease onset is too narrow in this SCA7 line for pursuit of a meaningful study. However, in the course of maintaining this line, we detected a knockin positive individual with reduced dis ease severity, and upon breeding, this SCA7 knockin subline did not display onset of ataxia until 12 to 14 weeks of age and did not succumb to disease until 24 to 28 weeks of age. When we characterized these mice, we determined that their CAG repeat mutation had contracted to 210 CAGs ( fig. S9A ) and named this new subline the "SCA7 r210" knockin model. Using a neurological screening exam, we determined that SCA7 r210 mice exhibit motor impairment by 12 weeks of age but do not display severe neurological dysfunction until after 18 weeks of age ( fig. S9, B and C) . We also performed ERG analysis and doc umented visual impairment at 9 weeks of age (figs. S10 and S11), in contrast to control mice ( fig. S12 ). Hence, we chose to pursue a pre clinical intervention trial with this new SCA7 knockin model and decided to test IVI delivery of Ataxin-7 ASO at 9 weeks of age, as we confirmed substantial vision loss at this time point in the SCA7 r210 mice ( fig. S13, A and B) . For the preclinical intervention trial, we used the same outcome measures used previously, but with a differ ent time line (fig. S14 ).
To determine whether Ataxin-7 ASO treatment can achieve robust and sustained knockdown of polyQexpanded Ataxin7, we compared the extent of Ataxin7 protein aggregation between Ataxin-7 ASOtreated eyes and vehicletreated eyes in SCA7 r210 mice at 9 weeks after IVI and observed a marked reduction in Ataxin7 aggregation in ASOtreated eyes, based on immunostaining of retinal sections and filter trap assay (Fig. 8, A to C) . We then considered visual function by tracking ERG responses at 6 and 9 weeks after IVI. At 6 weeks after IVI, maximal bwave amplitudes for both cone photoreceptors and rod photoreceptors were markedly increased in the Ataxin-7 ASOtreated eyes of SCA7 r210 knockin mice (Fig. 8D, top) , indicating that therapeutic benefit can be achieved even after substantive visual dysfunction is established. However, Ataxin-7 ASOtreated eyes still showed impairments compared to wildtype animals. Preservation of rod photoreceptor function in SCA7 r210 mice treated after symptom onset far exceeded that of cone photoreceptor function (Fig. 8D, bottom) , which is consistent with the more rapid loss of cone function in SCA7 conerod dystrophy. At 9 weeks after IVI, we observed no improvements in cone photo receptor function with Ataxin-7 ASO treatment (Fig. 8E, top) , whereas rod photoreceptor function was improved also at this later time point (Fig. 8E, bottom) compared to vehicletreated eyes. We also measured retinal layer thickness and quantified photoreceptor gene expression at the 9week postIVI time point. At this time point, the treatment did not induce improvements ( fig. S15, A and B) . Last, to assess the duration of action of Ataxin-7 ASO knockdown, we re peated the Ataxin-7 ASO prevention trial, but this time in the SCA7 r210 mice, and found that visual function is improved with Ataxin-7 ASO knockdown over 11 weeks after IVI ( fig. S16, A and B) .
DISCUSSION
ASOs are chemically modified singlestranded nucleic acids that form heteroduplexes with their target RNAs, and in the case of DNARNA heteroduplex formation, the targeted RNA is degraded by RNase H1 (29, 30) . The production of protein from target mRNA is then typically reduced by greater than 50%. Because of impressive advances in their chemistry, ASOs exhibit markedly increased po tency and duration of action, while displaying limited toxicity, especially in the CNS. Successful development of an oligonucleotide therapy to treat autosomal recessive spinal muscular atrophy by increasing survival of motor neuron (SMN) protein expression from the paralogous (A) Retinal histology of untreated nontransgenic control and SCA7 266Q mice at 6 weeks after IVI of 50 g of Ataxin-7 ASO in the right eye and IVI of PBS in the left eye. Sections were stained with hematoxylin and eosin. OS, outer segments; IS, inner segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar, 20 m. (B) Quantification of thickness for indicated retinal layers from (A). *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA with post hoc Tukey test. Comparison of thickness for PBS-treated eyes versus Ataxin-7 ASO-treated eyes was significant by t test for OS + IS (P < 0.05) and for IPL (P < 0.05). n = 4 to 5 mice per group. (C) Quantification of expression of indicated genes in retinal RNAs by RT-PCR analysis for SCA7 266Q mice at 6 weeks after IVI of 50 g of Ataxin-7 ASO in the right eye and IVI of PBS in the left eye. *P < 0.05, ***P < 0.001, ANOVA with post hoc Tukey test. Comparison of RNA expression for PBS-treated SCA7 mice versus Ataxin-7 ASO-treated SCA7 mice was significant by t test for M-cone opsin (M-opsin; P < 0.001) and for S-cone opsin (S-opsin; P < 0.05). n = 5 to 7 mice per group. (D) Quantification of histone H2B ubiquitination at the promoters of indicated genes by real-time PCR analysis of retinal DNAs isolated by ChIP from SCA7 266Q mice at 6 weeks after IVI of 50 g of Ataxin-7 ASO in the right eye and IVI of PBS in the left eye. *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA with post hoc Tukey test. n = 5 to 9 mice per group. (E) Quantification of histone H3 acetylation at the enhancers/promoters of indicated genes by real-time PCR analysis of retinal DNAs isolated by ChIP from SCA7 266Q mice at 6 weeks after IVI of 50 g of Ataxin-7 ASO in the right eye and IVI of PBS in the left eye. *P < 0.05, **P < 0.01, ***P < 0.001, ANOVA with post-hoc Tukey test. n = 4 to 6 mice per group. RER, rhodopsin enhancer region; LCR, locus control region of M-opsin; SER, S-opsin enhancer region. Error bars indicate SEM.
gene SMN2 through alternative splicing has demonstrated that periodic CNS delivery by intrathecal injection is a viable regimen for human patients (21) , heralding a powerful new approach for neurotherapeutics. Although such a therapy for spinal muscular atrophy is an incredible advance, it is still unclear whether similar approaches can be applied to neurodegenerative proteinopathies, where dosage reduction of a target misfolded protein product is the treatment goal. SCA7 is a rare neurodegenerative disorder caused by a dominant gainoffunction CAGpolyQ repeat expansion in one of the two ATAXIN-7 genes in an affected patient. In addition to significant neurological abnormalities due to dysfunction of the cerebellum, brainstem, and corticospinal tracts, SCA7 patients develop an un usual form of retinal degeneration, known as a conerod dystrophy (31) . SCA7 is also unique among neurodegenerative repeat diseases because, of all such disorders, it displays the most marked anticipa tion, with many patients presenting before the age of 30 years, in many cases before the onset of disease in their affected parent, de spite the fact that the affected parent is more than two or three de cades older than their affected child (6) . On the basis of clinical experience, SCA7 patients can present with either neurological signs or vision loss, and retinal degeneration is the initial presentation in such childhood, juvenile, or young adult SCA7 patients with ≥59 CAG repeats (8, 9) . Because of these clinical demographics, SCA7 retinal degeneration also tends to progress more rapidly in these younger SCA7 patients than in older patients who typically present with ataxia (8) . Furthermore, the eye is a highly accessible neural tissue, and evaluation of retinal function can be performed in an objective, quantitative fashion. For all these reasons, SCA7 retinal disease offers an unparalleled opportunity to evaluate ASO dosage reduc tion therapy in a discrete and definitive manner.
Here, we have taken the first steps toward developing an antisense based therapy for SCA7 by targeting Ataxin-7 with a specific ASO. After an extensive process of oligonucleotide design, manufacture, and screening, we identified two lead ASOs: one directed against the Ataxin-7 RNA and one directed against expanded CAG repeatcontaining RNA. We validated these lead ASOs for knockdown efficacy in vitro and tested them for potency and toxicity in vivo. To Here, we see densitometry quantification of Ataxin-7 immunoreactivity in filter trap assays at 6 weeks after injection. **P < 0.01, ***P < 0.001, ANOVA with post hoc Tukey test. n = 5 mice per group. (C) Quantification of mean maximal b-wave amplitudes for ERG analysis performed on untreated wild-type (nontransgenic) and SCA7 266Q mice at 4 weeks after IVI of 50 g of CAG-ASO in the right eye and IVI of PBS in the left eye. **P < 0.01, ***P < 0.001, ANOVA with post hoc Tukey test. Comparison of mean b-wave amplitudes for PBS versus Ataxin-7 ASO was significant by t test for the scotopic (rod) response (P < 0.05) and the photopic (cone) response (P < 0.05). n = 8 to 11 mice per group. (D) Quantification of mean maximal b-wave amplitudes for ERG analysis performed on untreated wild-type (nontransgenic) and SCA7 266Q mice at 6 weeks after IVI of 50 g of CAG-ASO in the right eye and IVI of PBS in the left eye. **P < 0.01, ***P < 0.001, ANOVA with post hoc Tukey test. n = 7 to 14 mice per group. Error bars indicate SEM.
achieve delivery to retinal photoreceptors, we established IVI as a viable and highly reproducible technique in SCA7 knockin mice and demonstrated that IVI could achieve marked, sustained knock down of Ataxin-7 expression. There is good reason to expect that IVI will be an effective delivery route for ASO treatment of SCA7 retinal degeneration, as fomivirsen, the very first ASO drug ever ap proved by the U.S. Food and Drug Administration, is delivered by IVI as a treatment for cytomegalovirus retinitis (32 ASO dosage reduction can be "nonallele specific," meaning that both the disease allele and the normal allele mRNAs are targeted, or "allele specific," meaning that the disease allele is selec tively targeted, usually through a single nucleotide polymorphism that is in linkage with the disease allele. Although allelespecific targeting would be ideal, studies in mouse models of HD have established the safety and efficacy of non-allelespecific ASOs (35, 36) . We addressed the issue of whether concom itantly targeting the normal Ataxin-7 gene would produce impaired function or toxicity in the eye by performing IVI of Ataxin-7 ASO in wildtype control mice and then assessing their visual function. We did not observe any visual impairment in control mice subjected to Ataxin-7 ASO knockdown, even when Ataxin-7 mRNA expression was reduced by >70%. As ATAXIN-7 has three homologues in mammals, known as ATAXIN-7-like1, , and ATAXIN-7-like 3, certain ATAXIN7 functions could be compensated for by these homologues. ATAXIN7-like3 is known to reside in the STAGA coactivator complex with ATAXIN7 and has been shown to play a role in regulating the STAGA deubiquitinase module (37) . Thus, although our results indicate that non-allelespecific Ataxin-7 ASO therapy is likely to be well tolerated, we did not follow ASOtreated wildtype mice long enough to completely rule out potential ocular or systemic toxicity. Hence, as we observed equivalent targeting of Ataxin-7 mutant and normal alleles in treated SCA7 knockin mice, an ideal non-allelespecific ASO therapy should achieve knock down of no more than 70% to obviate such toxicity concerns. Fur thermore, our preclinical trial work relied on mouse models of SCA7 retinal degeneration, which recapitulate the conerod dystrophy phenotype but cannot completely represent this disease phenotype, because murine photoreceptor complexity and retinal anatomical organization differ from those of the human. These limitations of our study necessitate more detailed and extensive experimentation to rule out potential ontarget or offtarget toxicities of Ataxin-7 ASO knockdown and require that we be circumspect in our extrapolation of our results to human SCA7 patients.
Although presymptomatic diagnosis by genetic testing can be pursued in atrisk children of SCA7 patients, currently most SCA7 patients do not come to diagnosis until they display ataxia or impaired vision. Hence, in many cases, initiation of therapy will not be possible until after SCA7 patients develop significant symptomatology. As part of this study, we piloted the use of three differ ent ophthalmological testing modalities on two SCA7 patients and observed variable retinal degeneration. We performed a follow up examination on the more severely affected patient and documented rapid dis ease progression based on increased macular auto fluorescence and more extensive photo receptor later degeneration on OCT, accompanied by very poor light detection across the retina on microperimetry. For these reasons, we pursued a preclinical intervention trial, where we tested whether IVI delivery of Ataxin-7 ASO would be effective in SCA7 knockin mice with significant retinal disease. This study illustrated that Ataxin-7 ASO therapy could reduce protein aggrega tion for the duration of the trial and could amelio rate impaired visual function for both rods and cones at the initial posttreatment time point. However, at the final time point, Ataxin-7 ASO therapy only ameliorated rod photoreceptor function but was in effective for cone photoreceptor function, retinal his topathology, and gene expression alterations. Because cone photoreceptor dysfunction begins earlier than rod photoreceptor abnormalities and proceeds much more rapidly (16), by 9 weeks of age, the time point for ASO delivery for the SCA7 r210 knockin mice, cone photoreceptor function is reduced by ~70%. How ever, for rod photoreceptor function, where SCA7 r210 mice exhibit a decline of ~40% of their scotopic ERG responses by 9 weeks of age, Ataxin-7 ASO treatment did retard disease progression. Hence, given the ag gressive nature of disease in the SCA7 knockin mice, our results suggest that Ataxin-7 ASO treatment might ameliorate disease progression even when adminis tered after symptoms develop. As we have shown that SCA7 cerebellar degeneration is reversible in mice upon termination of mutant protein expression (38), we conclude that robust knockdown of ATAXIN7 ex pression might slow disease progression, even when SCA7 patients have significant disease, but we antici pate that there is likely a point at which disease be comes too severe to allow for meaningful intervention. Determining the threshold at which a beneficial response is no longer possible will be a challenge for SCA7 therapy development, as it will be for all neurode generative disorders.
MATERIALS AND METHODS

Study design
The primary objective of this study was to determine whether ASO knockdown therapy is an effective treat ment for SCA7 retinal degeneration. ASOs were de signed and screened for efficacy of knockdown in cell lines and in wildtype mice in experiments that used quantitative realtime PCR assays and Western blot analysis. ASOs were tested in preclinical trials in SCA7 knockin mouse models, with aggregate accu mulation, visual function, retinal histology, and gene expression as the outcome measures. The preclinical trials, which were approved by and performed in accordance with the University of California, San Diego and Duke Institutional An imal Care and Use Committees, adhered to a protocol where we arbitrarily divided littermates and balanced genders between experi mental groups, with behavioral testing performed by investigators blinded to the treatment group of the mice. We based our group sizes on power analysis to achieve 80% likelihood of detection of a 30% rescue of phenotypes, using the G*Power 3.1 software package (39) . As part of this study, we performed ophthalmologic evalua tions of a set of SCA7 patients, tracking disease progression over time in one case. For all experiments, replicate numbers are stated in the figure legends.
Statistical analysis
All data were prepared for analysis with standard spreadsheet software (Microsoft Excel). Statistical analysis was performed using Prism 6.0 (GraphPad Software) or SigmaStat (Systat Software). For ANOVA, if statistical significance (P < 0.05) was achieved, then we performed post hoc analysis to account for multiple comparisons. All t tests were twotailed Student's t test, and the level of significance () was always set to 0.05.
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